BRCA2 and ovarian cancer: Traditionally, a threshold of greater than 10% lifetime ovarian cancer risk was used, allowing for RRSO in women carrying BRCA1, BRCA2, or mismatch repair gene mutations, which confer lifetime ovarian cancer risk well in excess of 10% [76].